Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GPR88 | Q9GZN0 | 11/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7788180 | 0.91 | F10 (0.38) | F10ALDH1A1MAPTF2KDM4E | |
| SCHEMBL7194808 | 0.89 | F10 (0.42) | F10ALDH1A1MAPTF2KDM4E | |
| SCHEMBL7187004 | 0.87 | MAPT (0.48) | F10ALDH1A1MAPTF2LMNA | |
| SCHEMBL7197221 | 0.85 | ALDH1A1 (0.37) | F10ALDH1A1MAPTF2KDM4E | |
| SCHEMBL7788768 | 0.84 | ATM (0.40) | F10ALDH1A1MAPTLMNAITGB3 | |
| SCHEMBL7191718 | 0.81 | ALDH1A1 (0.36) | ALDH1A1GPR88ITGB3ITGA2B | |
| SCHEMBL7789604 | 0.79 | ALDH1A1 (0.35) | ALDH1A1ITGB3ITGA2B | |
| SCHEMBL7788746 | 0.79 | SMN1; SMN2 (0.40) | ALDH1A1ITGB3ITGA2B | |
| SCHEMBL7194899 | 0.77 | ITGB3 (0.44) | F10ALDH1A1MAPTLMNAITGB3 | |
| SCHEMBL7789969 | 0.77 | CYP26A1 (0.42) | F10ALDH1A1MAPTF2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6589972-B2 | Anticancer agents, osteoporosis, arteriosclerosis, restnosis,vision defects | BAYER AKTIENGESELLSCHAFT (DE) | 2003-07-08 | — | — | US | disclosed |
| EP-1147079-A2 | BETA-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2001-10-24 | — | — | EP | disclosed |
| US-20010031788-A1 | Beta-phenylalanine derivatives as integrin antagonists | SCHOOP ANDREAS (DE) | 2001-10-18 | — | — | US | disclosed |
| US-6291503-B1 | β-phenylalanine derivatives as integrin antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-18 | — | — | US | disclosed |
| WO-2000041469-A2 | β-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031788-A1 | Beta-phenylalanine derivatives as integrin antagonists | ITGB4, ITGA4, ITGB2 | F10 1671/4885ALDH1A1 2010/4885MAPT 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.